Most lists of "NAD+ benefits for women" are copied from the same longevity talking points: more energy, sharper focus, better skin, slower aging. Almost none of them tell you which of those claims were ever tested in women, and in which women.
That second question matters more than it sounds. A 30-year-old and a 52-year-old in the middle of perimenopause are not running the same biology, and the research that gets quoted rarely separates them.
So here's the short version before the details. A handful of controlled trials have enrolled postmenopausal women specifically. One tested an NAD+ precursor, three tested resveratrol (a compound often paired with NAD+), and none tested NAD+ for hot flashes. What they found is real, narrower than the marketing, and worth knowing if you're 45 or older and wondering whether any of this applies to you.
- NAD+ falls with age in women too. In human skin samples, NAD+ levels dropped with age in both sexes (Massudi et al., 2012), and plasma NAD+ is lower in older adults (Clement et al., 2019).
- The one precursor trial run only in postmenopausal women was small and specific. NMN at 250 mg a day for 10 weeks raised muscle insulin sensitivity by 25% in 13 women, and changed nothing else that was measured, including body composition (Yoshino et al., Science, 2021).
- The longest trials in this age group tested resveratrol, not NAD+. At 75 mg twice a day for 12 months, postmenopausal women improved on cognitive tests and bone density compared with placebo (the RESHAW trials).
- Perimenopausal brain fog is real, and usually temporary. In 2,362 women followed for four years, the dip in learning on memory tests during perimenopause rebounded after menopause (Greendale et al., Neurology, 2009).
- No controlled trial has shown NAD+ helps hot flashes or night sweats. Those symptoms are driven by estrogen, and NAD+ isn't a hormone.
What Actually Changes Around 45
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses to turn food into usable energy. It also feeds a family of enzymes called sirtuins, which help cells respond to stress. You can't feel your NAD+ level, but two things about it are fairly well established.
First, it goes down with age. The clearest human data comes from tissue and blood, not from symptoms. Researchers in Sydney measured NAD+ in pelvic skin samples from 49 people aged 0 to 77 and found a strong negative correlation with age in men and a significant one in women (Massudi et al., PLoS One, 2012). A later study of blood samples from adults aged 20 to 87 found plasma NAD+ declined with age as well (Clement et al., Rejuvenation Research, 2019).
Second, the breakdown side speeds up. An enzyme called CD38 consumes NAD+, and its expression and activity rise with age. In the Mayo Clinic work that identified this, CD38 was required for the age-related NAD+ decline in mice (Camacho-Pereira et al., Cell Metabolism, 2016). That's the reason some formulas pair NAD+ with quercetin, which inhibits CD38 in lab studies.
None of this is specific to menopause. It happens in men on roughly the same timeline. What's different for women in their mid-40s to mid-50s is that the NAD+ decline overlaps with the menopause transition, and the two produce complaints that sound alike: tiredness, a foggier afternoon, less resilience after a bad night.
The Brain Fog Part Is Real, and Mostly Temporary
If you've felt slower at finding words or holding a list in your head in your late 40s, the research backs you up. The Study of Women's Health Across the Nation (SWAN) followed 2,362 women for four years and gave them the same memory and processing-speed tests repeatedly. Before menopause, women scored better each time they retook the tests, the ordinary practice effect. During perimenopause, that improvement stalled. After menopause, it came back to premenopausal levels (Greendale et al., Neurology, 2009).
The authors' reading was that transition-related cognitive difficulties "may be time-limited." That's reassuring, and it also sets a fair bar for any supplement. If most women's scores recover on their own after the transition, a product that claims to "fix" menopausal brain fog has to show it did better than time alone. None of the NAD+ products on the market have done that.
The One NAD+ Precursor Trial Run in Postmenopausal Women
In 2021, a team at Washington University in St. Louis published the first randomized trial of an NAD+ precursor in people, and they chose postmenopausal women as the participants. Twenty-five women, average age about 62, took either 250 mg of NMN (nicotinamide mononucleotide) a day or a placebo for 10 weeks. All of them were overweight and had blood sugar in the prediabetic range (Yoshino et al., Science, 2021).
The main result was specific. Muscle insulin sensitivity, measured with the most rigorous method available (a clamp test), was 25% higher after NMN and unchanged after placebo. Insulin signaling in muscle tissue improved too.
What didn't change is just as useful to know. Body composition, including fat mass and belly fat, stayed the same. So did blood pressure, fasting glucose, blood lipids, and liver fat. And muscle NAD+ content itself didn't rise; the researchers saw more NAD+ turnover instead. Nobody reported side effects, and routine blood tests stayed normal in both groups.
So what does this trial support? That an NAD+ precursor can change how muscle handles sugar in this group of women. It doesn't support weight loss, it wasn't designed to test energy or mood, and 13 women on NMN is a small number. It also tested NMN, not NAD+ itself. Swallowed NAD+ is largely broken down into smaller precursors before absorption, which is why precursor trials are the closest evidence we have for capsules. (We cover that digestion step in our piece on NAD+ side effects.)
Resveratrol: The Longest Trials in This Age Group
The most substantial research on women past menopause comes from a supplement that's often combined with NAD+, not from NAD+ itself. Researchers at the University of Newcastle in Australia ran a series of resveratrol trials called RESHAW, always at the same dose: 75 mg twice a day, 150 mg in total.
The pilot enrolled 80 postmenopausal women aged 45 to 85 for 14 weeks. Compared with placebo, resveratrol produced 17% increases in cerebrovascular responsiveness (how well blood flow to the brain rises when it's needed), along with better verbal memory and overall cognitive performance (Evans et al., Nutrients, 2017). Mood tended to improve, but not significantly.
The main trial then ran for 24 months with 125 women who completed it, crossing each group over from placebo to resveratrol or the reverse at the halfway point. Over the first 12 months, resveratrol improved overall cognitive performance compared with placebo (Thaung Zaw et al., Nutrients, 2020). Lumbar spine bone density rose by 0.014 g/cm² relative to placebo, about 1.3%, and a marker of bone breakdown fell 7.24% (Wong et al., Journal of Bone and Mineral Research, 2020). A separate report from the same trial found an 18% reduction in a composite pain score and better scores on menopause-related quality of life, including the vasomotor items on the questionnaire (Thaung Zaw et al., Menopause, 2020).
Two caveats keep this in proportion. The resveratrol maker supplied the capsules and some of the funding for RESHAW (it had no role in the analysis, according to the authors), and the trials tested resveratrol on its own, not combined with NAD+. And resveratrol doesn't always deliver: in a 12-week trial of 75 mg a day in non-obese postmenopausal women with normal blood sugar, it produced no metabolic improvement at all (Yoshino et al., Cell Metabolism, 2012). We go through both sides in NAD+ and Resveratrol: Why the Pairing Outlived the Hype.
What the Evidence Covers, and What It Doesn't
Put the trials side by side and the picture is uneven. Some benefits people attach to NAD+ have direct support in women past menopause. Others borrow from animal work or from studies in men. And the symptom most women care about has no support at all.
| Claim | Tested in postmenopausal women? | What was found |
|---|---|---|
| Metabolism (how muscle uses sugar) | Yes, NMN, 10 weeks, 25 women | 25% better muscle insulin sensitivity; no weight change |
| Memory and thinking | Yes, resveratrol only | Better cognitive scores at 14 weeks and 12 months |
| Bone density | Yes, resveratrol only | About 1.3% higher spine density vs. placebo at 12 months |
| Energy and fatigue | Not as a main outcome | No direct evidence in this group |
| Hot flashes and night sweats | Not for NAD+ | No controlled NAD+ data; one resveratrol questionnaire signal |
| Weight loss | Measured, not found | Body composition unchanged with NMN |
Energy is the awkward one. It's the main reason women try NAD+, and it's the outcome least studied in them. Trials in mixed or older populations have reported inconsistent effects on fatigue, and the NMN trial above didn't measure it. If you try an NAD+ product for energy, you're running your own experiment, which is fine as long as you know that's what it is.
Why NAD+ Won't Touch Hot Flashes
Hot flashes and night sweats come from the brain's temperature control center reacting to falling and fluctuating estrogen. NAD+ doesn't contain estrogen, doesn't act like it, and hasn't been shown to change estrogen levels in a controlled study. That's why we'd be suspicious of any NAD+ product marketed as a replacement for the menopause treatments your doctor can prescribe.
Resveratrol is a partial exception worth being precise about. It's a phytoestrogen, a plant compound that can interact with estrogen receptors, and in RESHAW the questionnaire scores for menopause symptoms improved. That's one trial, measured as a secondary outcome. It's a reason for curiosity, not a reason to skip a conversation with your doctor about symptoms that are disrupting your sleep or work.
What NAD+ might reasonably do during this stage is support the cellular side of energy metabolism while the hormonal side does whatever it's going to do. That's a smaller promise. It's also the one the evidence can carry.
Who Should Talk to a Doctor First
For NAD+ and its precursors on their own, trials of up to 24 weeks haven't shown more side effects than placebo. The cautions for women mostly come from the ingredients commonly paired with it.
- If you have a hormone-sensitive condition, or a history of one, ask before taking any formula with resveratrol, because it can act on estrogen receptors.
- If you take a blood thinner or have surgery scheduled, mention resveratrol, which inhibits platelet clumping and may raise bleeding risk (MSKCC).
- If you take several prescription medications, ask your pharmacist. At 1 gram a day, resveratrol inhibited several liver enzymes that clear common drugs (Chow et al., 2010).
- Pregnancy and breastfeeding: there's no safety data, so skip it.
Anyone in active cancer treatment should clear any NAD+ product with their oncologist first; our NAD+ side effects article explains why.
How to Try It Sensibly
If you decide to try an NAD+ supplement in your late 40s or 50s, a few habits make the result easier to read:
Take it with breakfast. Food reduces the mild stomach upset some people notice, and it's how most trials dosed. Give it eight weeks before you judge it, since that's roughly the window where trials see changes in blood markers. Keep a short note of your energy, sleep and focus in the first week and again at week eight, because memory is a poor judge of slow changes. And change one thing at a time; if you start NAD+ the same month you start strength training, you won't know which one helped.
Check the resveratrol dose on the label too. The RESHAW trials used 150 mg a day. Many NAD+ products contain a fraction of that, or don't state the extract percentage, which makes the real dose impossible to know.
Where Soleu's NAD+ for Women Fits
We built a version of our NAD+ formula for women 45 and over because the resveratrol dose in it lines up closely with the RESHAW trials. It's the same three-ingredient formula as our original NAD+, sold with information aimed at this stage of life.
NAD+ for Women 45+ with Resveratrol & Quercetin
Per two-capsule serving: 500 mg NAD+, 250 mg quercetin dihydrate, and 150 mg Japanese knotweed extract standardized to 98% resveratrol (about 147 mg of resveratrol). Hormone-free, no nicotinic acid, 60 vegetable capsules.
See the formula and labelTo be plain about it: this formula hasn't been tested in its own clinical trial. The RESHAW results came from resveratrol alone, the NMN results came from a precursor, and 147 mg is close to 150 mg but not identical. We think that's worth telling you. We don't think it entitles us to promise the same results.
Frequently Asked Questions
Is NAD+ good for women in menopause?
NAD+ levels fall with age in both sexes, and one 10-week trial in postmenopausal women found the precursor NMN improved muscle insulin sensitivity by 25%. No trial has shown NAD+ relieves menopause symptoms such as hot flashes. It may support cellular energy during this stage; it isn't a menopause treatment.
Does NAD+ help with perimenopause fatigue?
It hasn't been tested as a main outcome in perimenopausal women. Some people report more energy, but trials in other groups have been inconsistent on fatigue. If you try it, give it about eight weeks and track your energy in writing so you can judge the change honestly.
Does NAD+ affect estrogen?
No controlled study has shown that NAD+ changes estrogen levels, and NAD+ is not a hormone. Resveratrol, which is often paired with NAD+, is a phytoestrogen that can interact with estrogen receptors, which is why women with hormone-sensitive conditions should ask a doctor before taking formulas that contain it.
Will NAD+ help me lose weight during menopause?
The evidence says no. In the NMN trial in postmenopausal women, fat mass, belly fat and body weight didn't change over 10 weeks even though muscle insulin sensitivity improved.
What is the downside of taking NAD+?
In capsule form, the side effects reported in precursor trials were mild and no more common than on placebo, mostly occasional stomach upset or headache. The bigger considerations for women are the added ingredients: resveratrol and quercetin can matter if you take a blood thinner or have a hormone-sensitive condition. There's also no long-term data beyond about six months.
How long does NAD+ take to work for women?
Blood NAD+ levels rise within about two weeks in precursor trials. Changes in measured outcomes appeared at 10 weeks in the NMN trial and at 14 weeks to 12 months in the resveratrol trials. Eight weeks is a reasonable minimum before deciding whether it's doing anything for you.
The Bottom Line
For women past 45, the case for NAD+ rests on a small but real set of trials: one showing a precursor improved how muscle handles sugar, and several showing resveratrol, the ingredient most often paired with it, helped cognition and bone density over a year. None of them tested energy directly, and none showed NAD+ relieves hot flashes.
If you want support for the cellular side of midlife energy and you're comfortable with evidence that's promising rather than settled, it's a reasonable thing to try for two months. If hot flashes and broken sleep are the main problem, start with your doctor.
Related Reading
- NAD+ Side Effects: Why a Capsule and an IV Drip Aren't the Same Risk: what capsule trials recorded, and who should skip NAD+.
- NAD+ and Resveratrol: Why the Pairing Outlived the Hype: the full case for and against the combination.
- Can You Take Quercetin With NAD+?: CD38 and why quercetin is in the stack.
- NMN Benefits: What Does the Science Actually Say in 2026?: the wider precursor research.
Sources
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021. PMC8550608
- Greendale GA, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology, 2009. PMC2690984
- Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 2012. PMC3407129
- Clement J, et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Research, 2019. PMC6482912
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 2016. PMC4911708
- Evans HM, Howe PR, Wong RH. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial. Nutrients, 2017. PMC5295071
- Thaung Zaw JJ, Howe PRC, Wong RHX. Sustained cerebrovascular and cognitive benefits of resveratrol in postmenopausal women. Nutrients, 2020. PMC7146200
- Wong RH, et al. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. Journal of Bone and Mineral Research, 2020. PMC7689937
- Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women. Menopause, 2020. PMID 32881835
- Yoshino J, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism, 2012. PMC3496026
- Memorial Sloan Kettering Cancer Center. Resveratrol (About Herbs). mskcc.org
- Chow HH, et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res, 2010. PMC2933312
- ClinicalTrials.gov. NCT04841499: effects of a seven-day nicotinamide riboside and pterostilbene supplement on menopausal symptoms. clinicaltrials.gov